Latest & greatest articles for breast cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer screening

1. Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer

or 42 CommGuideCancerMCIPsycINFO 1. (mass screening or multiphasic screening or screen or screened or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical (...) or screening).ti,ab. or "early detection of cancer"/ 20. (neoplasms/ or breast neoplasms/ or colorectal neoplasms/ or uterine cervical neoplasms/ or carcinoma, ductal, breast/ or "hereditary breast and ovarian cancer syndrome"/ or inflammatory breast neoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs. 21. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 22. 20 or 21 23

2020 Community Preventive Services Task Force

2. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) for breast cancer diagnosis? What is the comparative clinical effectiveness of synthetic 2D mammography compared with conventional 2D digital mammography obtained with 3D digital tomosynthesis? What is the cost effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer screening or diagnosis? What are the evidence-based guidelines regarding the use of 3D digital tomosynthesis for breast cancer screening and diagnosis? Key Message Seven

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging (Abstract)

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breast cancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breast cancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breast cancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at Breast Cancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data

2019 EvidenceUpdates

4. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial Full Text available with Trip Pro

Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations of standard digital mammography. This study aimed to compare first-generation digital breast tomo-synthesis including two-dimensional (2D) synthetic mammograms versus digital mammography in a population-based screening (...) cancer, stratified by screening technique (ie, digital breast tomosynthesis and digital mammography). A log-binomial regression model was used to estimate the efficacy of digital breast tomosynthesis versus digital mammography, defined as the crude risk ratios (RRs) with 95% CIs for screen-detected breast cancer for women screened during the recruitment period. A per-protocol approach was used in the analyses. This trial is registered at ClinicalTrials.gov, number NCT02835625, and is closed

2019 EvidenceUpdates

5. Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. Full Text available with Trip Pro

Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. The purpose of this guidance statement is to provide advice to clinicians on breast cancer screening in average-risk women based on a review of existing guidelines and the evidence they include.This guidance statement is derived from an appraisal of selected guidelines from around the world that address breast cancer screening, as well as their included evidence. All national (...) is all clinicians, and the target patient population is all asymptomatic women with average risk for breast cancer.In average-risk women aged 40 to 49 years, clinicians should discuss whether to screen for breast cancer with mammography before age 50 years. Discussion should include the potential benefits and harms and a woman's preferences. The potential harms outweigh the benefits in most women aged 40 to 49 years.In average-risk women aged 50 to 74 years, clinicians should offer screening

2019 Annals of Internal Medicine

6. Accuracy of Self-Report for Cervical and Breast Cancer Screening

Accuracy of Self-Report for Cervical and Breast Cancer Screening Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and Breast Cancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and Breast Cancer Screening Health Services Research & Development Management eBrief no. 152 » Issue 152 April 2019 (...) The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Accuracy of Self-Report for Cervical and Breast Cancer Screening Guideline-based breast and cervical cancer screening are considered essential health benefits and are fundamental components of high-quality primary care services in the United States. The aim of cancer screening is to identify cancers in an early stage when treatment is more likely to be effective. Accurate measurement of cancer screening rates is vital

2019 Veterans Affairs - R&D

7. Screening for Breast Cancer in Average-Risk Women Full Text available with Trip Pro

reviews showed that women aged 39 to 49 years derived the lowest absolute benefit in terms of deaths prevented ( , ) ( ). Observational studies showed larger relative reductions in breast cancer mortality ( ). Evidence from RCTs (fair quality) and observational studies (poor quality) did not show a reduction in the incidence of advanced disease with breast cancer screening in women aged 39 to 49 years (pooled results from 4 RCTs: relative risk, 0.98 [95% CI, 0.74 to 1.37]) ( ). Screening intervals (...) diagnostic accuracy characteristics regarding cancer detection, false-positive results, recalls, and biopsy rates. Compared with conventional mammography, DBT seems to reduce recall rates and increase cancer detection ( ). The effect of these more sensitive imaging methods on the spectrum of detected disease and associated screening benefits and harms, including overdiagnosis, is not known. Alternative or Adjunctive Tests to Screening Mammography in Women Who Have Dense Breasts Increased breast density

2019 American College of Physicians

8. Accuracy of Self-report for Cervical and Breast Cancer Screening

Accuracy of Self-report for Cervical and Breast Cancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening Health Services Research & Development Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening to the ESP Report RSS feed Prepared by: Evidence Synthesis Program (ESP) Coordinating (...) Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Recommended Citation: Anderson J, Bourne D, Peterson, K, Mackey K. Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening. VA ESP Project #09-199; 2019. Download PDF: , Purpose The ESP Coordinating Center (ESP CC) is responding to a request from the VHA Performance Workgroup for an evidence brief on the accuracy of patient self-report for cervical and breast cancer screening. Findings from

2019 Veterans Affairs Evidence-based Synthesis Program Reports

9. Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk

Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breast cancer with mammography results in a modest reduction in breast cancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives

2018 Canadian Task Force on Preventive Health Care

10. Should This Woman With Dense Breasts Receive Supplemental Breast Cancer Screening?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

for breast cancer. In addition, for women with dense breasts, small tumors may be missed on mammography and the sensitivity of screening is diminished. At the time of publication, 35 states had passed laws mandating that breast density be reported in the letters that radiologists send to women with their mammogram results. The mandated language may be challenging for patients to understand, and such reporting may increase worry for women who are told that their risk for breast cancer is higher than (...) Should This Woman With Dense Breasts Receive Supplemental Breast Cancer Screening?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Breast cancer will develop in 12% of women during their lifetime and is the second leading cause of cancer death among U.S. women. Mammography is the most commonly used tool to screen for breast cancer. Considerable uncertainty exists regarding the age at which to begin screening and the optimal screening interval. Breast density is a risk factor

2018 Annals of Internal Medicine

11. Knowledge, Beliefs, and Attitudes About Breast Cancer Screening in Latin America and the Caribbean: An In-Depth Narrative Review Full Text available with Trip Pro

Knowledge, Beliefs, and Attitudes About Breast Cancer Screening in Latin America and the Caribbean: An In-Depth Narrative Review Purpose Breast cancer (BCA) is the most common cancer and leading cause of cancer mortality among women in Latin America and the Caribbean (LAC), and the number of deaths from BCA is expected to continue to increase. Although barriers to care include the physical accessibility of screening resources, personal and cultural barriers must be explored to understand (...) to identify articles. Thirty-five articles were included according to inclusion and exclusion criteria. Results Themes identified in the literature included knowledge about screening procedures and cause of cancer; knowledge sources; catalysts and deterrents for screening, such as family support, family history; social support or taboo, fear, self-neglect, cost, and transportation; and the perception of the screening experience. Conclusion In addition to physical availability of resources and health care

2018 Journal of global oncology

12. Breast cancer screening

choose to begin biennial screening between the ages of 40 and 49 years. • For women who are at average risk for breast cancer , most of the benefit of mammography results from biennial screening during ages 50 to 74 years. Of all of the age groups, women aged 60 to 69 2016 5. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. BACKGROUND: Breast cancer is the most common malignant disease diagnosed in women worldwide (...) Breast cancer screening Top results for breast cancer screening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might

2018 Trip Latest and Greatest

13. The Association of Health Literacy with Breast Cancer Knowledge, Perception and Screening Behavior Full Text available with Trip Pro

The Association of Health Literacy with Breast Cancer Knowledge, Perception and Screening Behavior The incidence of breast cancer among Iranian women is increasing, and 70% of patients are diagnosed at advanced stages. The current study aimed at evaluating the association of health literacy (HL) with breast cancer knowledge, perception, and screening behavior in women.The current cross- sectional, descriptive study was conducted on 250 women who referred to health centers in Zahedan, Iran. Data (...) ), and with perceived susceptibility.Interventions to enhance breast cancer knowledge and screening should notice the HL of women.

2018 European journal of breast health

14. Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers. Full Text available with Trip Pro

Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers. In 30 states, women who have had screening mammography are informed of their breast density on the basis of Breast Imaging Reporting and Data System (BI-RADS) density categories estimated subjectively by radiologists. Variation in these clinical categories across and within radiologists has led to discussion about whether automated BI-RADS density should (...) be reported instead.To determine whether breast cancer risk and detection are similar for automated and clinical BI-RADS density measures.Case-control.San Francisco Mammography Registry and Mayo Clinic.1609 women with screen-detected cancer, 351 women with interval invasive cancer, and 4409 matched control participants.Automated and clinical BI-RADS density assessed on digital mammography at 2 time points from September 2006 to October 2014, interval and screen-detected breast cancer risk, and mammography

2018 Annals of Internal Medicine

15. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis Full Text available with Trip Pro

A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis Tumor cells disseminate early in tumor development making metastasis-prevention strategies difficult. Identifying proteins that promote the outgrowth of disseminated tumor cells may provide opportunities for novel therapeutic strategies. Despite multiple studies demonstrating that the mesenchymal-to-epithelial transition (MET) is critical for metastatic colonization, key regulators (...) that initiate this transition remain unknown. We serially passaged lung metastases from a primary triple negative breast cancer xenograft to the mammary fat pads of recipient mice to enrich for gene expression changes that drive metastasis. An unbiased transcriptomic signature of potential metastatic drivers was generated, and a high throughput gain-of-function screen was performed in vivo to validate candidates. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) was identified

2018 NPJ breast cancer

16. The overestimation and the inappropriate promotion of the benefits of mammographic screening in breast cancer research and interventions in the Gaza Strip. Full Text available with Trip Pro

The overestimation and the inappropriate promotion of the benefits of mammographic screening in breast cancer research and interventions in the Gaza Strip. There has been extensive debate about whether mammographic screening has done more good than harm. Recent reviews showed that women who undergo mammographic screening are more likely to have a tumour that was an overdiagnosis and therefore would not cause them problems. In the Gaza Strip, a strong forum of people advocate an increase (...) women have low survival rates because of the poor availability of mammography. Only three study groups mentioned harmful effects of mammographic screening. All educational materials had clear information on the benefits of mammographic screening but minimal information on its harms.Research in the Gaza Strip overestimated the reduction in breast cancer mortality that can be attributable to mammographic screening, and this would encourage women to undergo screening without knowing that it could harm

2018 Lancet

17. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. Full Text available with Trip Pro

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden.To evaluate the contributions associated with screening and treatment to breast cancer mortality reductions by molecular subtype based (...) , overall, and ER/ERBB2-specific breast cancer mortality rates from 2000 to 2012 for women aged 30 to 79 years relative to the estimated mortality rate in the absence of screening and treatment (baseline rate); mortality reductions were apportioned to screening and treatment.In 2000, the estimated reduction in overall breast cancer mortality rate was 37% (model range, 27%-42%) relative to the estimated baseline rate in 2000 of 64 deaths (model range, 56-73) per 100 000 women: 44% (model range, 35%-60

2018 JAMA

18. Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors Full Text available with Trip Pro

Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors First-degree relatives of women with breast cancer are under higher risk when compared with the general population. The aim of this study is to evaluate breast cancer screening behaviors of women who are first-degree relatives of women with breast cancer and factors affecting these behaviors.This descriptive study included 240 patient relatives, who agreed (...) to participate in the study through contact with first-degree relatives of 133 patients who were receiving breast cancer treatment at the Oncology and Chemotherapy unit of an university hospital in Turkey. Data were collected using the "Descriptive Characteristics Form," which consisted of socio-demographic characteristics, health history, breast cancer risk level and health beliefs as well as the "Breast Cancer Screening Behavior Evaluation Form".Out of the subjects, 17% reported doing breast self

2018 European journal of breast health

19. “Thanks for Letting Us All Share Your Mammogram Experience Virtually”: Developing a Web-Based Hub for Breast Cancer Screening Full Text available with Trip Pro

“Thanks for Letting Us All Share Your Mammogram Experience Virtually”: Developing a Web-Based Hub for Breast Cancer Screening The decision around whether to attend breast cancer screening can often involve making sense of confusing and contradictory information on its risks and benefits. The Word of Mouth Mammogram e-Network (WoMMeN) project was established to create a Web-based resource to support decision making regarding breast cancer screening. This paper presents data from our user (...) to explore the advantages and limitations of this approach. The second objective was to analyze what women want from a Web-based resource for breast cancer screening.We recruited a user design group on Facebook and conducted a survey within the group, asking questions about design considerations for a Web-based breast cancer screening hub. Although the membership of the Facebook group varied over time, there were 71 members in the Facebook group at the end point of analysis. We next conducted a framework

2017 JMIR cancer

20. The WISDOM Study: breaking the deadlock in the breast cancer screening debate Full Text available with Trip Pro

risk for a specific tumor type, generating new data that can inform best practices rather than to continue the rancorous debate. It is time to move from debate to wisdom by asking new questions and generating new knowledge. The WISDOM Study (Women Informed to Screen Depending On Measures of risk) is a pragmatic, adaptive, randomized clinical trial comparing a comprehensive risk-based, or personalized approach to traditional annual breast cancer screening. The multicenter trial will enroll 100,000 (...) The WISDOM Study: breaking the deadlock in the breast cancer screening debate There are few medical issues that have generated as much controversy as screening for breast cancer. In science, controversy often stimulates innovation; however, the intensely divisive debate over mammographic screening has had the opposite effect and has stifled progress. The same two questions-whether it is better to screen annually or bi-annually, and whether women are best served by beginning screening at 40

2017 NPJ breast cancer Controlled trial quality: uncertain